The Contrived Mutant p53 Oncogene – Beyond Loss of Functions by Kanaga Sabapathy
December 2015 | Volume 5 | Article 2761
Review
published: 10 December 2015
doi: 10.3389/fonc.2015.00276
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Ygal Haupt, 
Peter MacCallum Cancer Centre, 
Australia
Reviewed by: 
Alexandre Arcaro, 
University of Bern, Switzerland 
Giannino Del Sal, 
Laboratorio Nazionale Consorzio 
Interuniversitario Biotecnologie 
(LNCIB), Italy
*Correspondence:
Kanaga Sabapathy  
cmrksb@nccs.com.sg
Specialty section: 
This article was submitted to 
Molecular and Cellular Oncology, 
a section of the journal 
Frontiers in Oncology
Received: 11 September 2015
Accepted: 24 November 2015
Published: 10 December 2015
Citation: 
Sabapathy K (2015) The Contrived 
Mutant p53 Oncogene – Beyond 
Loss of Functions. 
Front. Oncol. 5:276. 
doi: 10.3389/fonc.2015.00276
The Contrived Mutant p53 
Oncogene – Beyond Loss 
of Functions
Kanaga Sabapathy1,2,3,4*
1Division of Cellular and Molecular Research, National Cancer Centre Singapore, Humphrey Oei Institute of Cancer 
Research, Singapore, 2Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore, 3Institute of 
Molecular and Cellular Biology, Singapore, 4Department of Biochemistry, Yong Loo Lin School of Medicine, National 
University of Singapore, Singapore
Mutations in p53 are almost synonymous with cancer – be it susceptibility to the disease 
or response to treatment – and therefore, are a critical determinant of overall survival.
As most of these mutations occur in the DNA-binding domain of p53, many of the
clinical correlations with mutant p53 have been initially relegated to the loss of its tran-
scription-dependent activities as a tumor suppressor. However, significant efforts over
the last two decades have led to the vast knowledge on the potential functions of the 
mutated p53 protein, which have been attributed to the physical presence of the mutant 
protein rather than the loss of its wild-type (WT) functions. Beyond the inhibitory effects 
of mutant p53 on the remaining WT protein that leads to the dominant-negative effect in 
the heterozygous state, mutant p53’s presence has also been significantly attributed to 
novel gain-of-functions that lead to addiction of cancer cells to its presence for survival, 
as well as for their ability to invade and metastasize, elevating it to a contrived oncogene 
that drives the cancer cells forward. This review will summarize the functional conse-
quences of the presence of mutant p53 protein on cellular and organismal physiology.
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MUTANT p53
p53, one of the earliest identified tumor suppressors, has been overwhelmingly confirmed to be 
the most mutated gene across all cancer types through the recent avalanche of cancer genome 
sequencing efforts (1). Mutations in p53 occur in about 90% of the cases in its central DNA-binding 
domain (DBD), thereby leading to loss of its transactivation properties that are often associated 
with its tumor-suppressor functions [reviewed in Ref. (2)]. During the course of the evolution of the 
transformed cell, mutant p53 derived from the mutated allele co-exists with the wild-type (WT) p53 
from the other allele for varying time periods, till the WT allele is generally lost through loss-of-
heterozygozity (LOH), resulting in the sole existence of only the mutant p53 (Figure 1). Like most of 
the tumor suppressors that have a direct impact on tumor growth upon their loss of function – thus 
qualifying them as tumor suppressors – mutations in p53 were also thought to lead to loss of most of 
its tumor-suppressor functions that regulate almost all aspects of cellular physiology. Interestingly, 
during the co-existence phase of both the WT and mutant p53 proteins, haploinsufficiency leads to 
propensity for increased tumor development, as has been demonstrated in Li–Fraumeni patients 
FiGURe 1 | Mutant p53 functions during the evolution of a cancer cell. The schematic represents the general evolution of a normal cell into a transformed cell 
(carcinoma), and the contexts in which mutant (Mut) p53 exerts its functions. p53 mutations are not present in the normal case and are induced upon genotoxic 
exposures in one allele. Hence, in the intermediate stage, the mutant p53 co-exists with the wild-type (WT) p53, until the loss of the wild-type allele by loss-of-
heterozygozity (LOH). Functionally, when p53 is unmutated, it can be activated and works as a tetramer. However, when one allele is mutated, there is reduced 
overall function resulting in haploinsufficieny, and also the dominant-negative effect of the mutant protein on the wild-type protein due to the formation of 
heterodimers (please see text for details). At the later stages when only the mutant p53 remains, it is unable to bind to canonical target sequences to turn on its 
targets, leading to loss of wild-type functions. In addition, mutant p53 acquires novel gain-of-functions to drive the growth, survival, and invasion of tumor cells.
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as well as in a large number of model organisms expressing the 
mutant p53 allele (3, 4). However, in contrast to most tumor sup-
pressors, mutant p53 is unique in the sense that it has not only lost 
its tumor-suppressor functions, but evidence accumulating over 
the last two decades has assigned a wide variety of advantages to 
the cancer cell of having the mutant p53 protein. In short, the 
advantages of having a mutant p53 to the growth and survival of 
the tumor cells can be classified as a mirror image of the tumor-
suppressor functions of WT p53 (Figure 2). Of interest is the fact 
that no other tumor suppressor has acquired such a wide array 
of novel functions as p53 when mutated, thereby elevating p53 
to the status of a “contrived” oncogene, entirely on the basis that 
its functions as a tumor suppressor are turned on its head when 
the gene gets mutated. In this review, I will discuss the novel and 
acquired functions of mutant p53, specifically focusing on the 
DBD mutations.
DOMiNANT-NeGATive FUNCTiONS OF 
MUTANT p53 – AT THe eARLY STAGeS
Generally, in the early phases of cancer development, mutated 
p53 co-exists with the WT allele until the latter is lost due to 
LOH. In this co-existence phase, haploinsufficiency is a gener-
ally observed phenomenon associated with tumor development 
(5). However, effects of the mutant p53 over the WT’s regular 
functions  –  in a dominant-negative (DN) manner  –  have also 
been noted. Several early studies indirectly illustrated this DN 
effect, especially through the overexpression of the mutant p53 in 
WT p53 expressing cells, or vice versa. However, direct evidence 
for the DN effect of the mutant p53 protein on the WT p53 was 
shown in co-overexpression studies, demonstrating the quench-
ing of WT p53’s ability to affect cellular transformation and trans-
activation of target genes, especially in transformed cell lines (6, 
FiGURe 2 | Mutant p53 – the contrived oncogene. The figure represents a mirror image of the functions of the wild-type and mutant p53 proteins. While 
wild-type p53 is a tumor suppressor, the mutant form represents not only a loss of these functions but also the acquisition of directly opposite functions. Many of the 
tumor-suppressor functions and the counteracting oncogenic functions by mutant p53 are represented as mirror-image pairs: cell death/cell survival; cell cycle 
arrest/cell proliferation; DNA-repair/genomic instability; senescence/invasion and metastasis; metabolic homeostasis/Warburg effect; restriction of angiogenesis and 
inflammation/increased angiogenesis and inflammation; restriction of stem cell plasticity and survival/increased reprograming and expansion, to highlight a few.
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7). Co-expression of WT p53 with mutant p53 was also shown to 
affect the conformation of the former into a mutant conformation 
due to co-translation with the mutant form (8). Moreover, WT 
p53 was suggested to be inactivated through oligomerization with 
mutant p53 (9), and by inhibition of WT p53’s ability to bind to 
target gene promoters in a specific manner (6, 10). Concomitant 
to the effects on target gene activation, DN effects were noted 
on WT p53’s ability to induce cell death (11) and ras-induced 
senescence (12). Consequently, large efforts to analyze the DN 
effects of tumor-derived p53 mutants on the activation of several 
target genes have been undertaken in a systematic way using 
the yeast model, which was able to classify mutations as either 
dominant or recessive (13), and has also led to the cataloging of 
p53 mutations based on the ability to regulate a large number of 
p53-target genes (14).
Although the DN phenomenon has been well demonstrated 
in a large series of studies, the question that remained was its 
relevance when mutant p53 is expressed from its endogenous 
locus. This was resolved with the generation of the p53 mutant 
knock-in mouse models, whereby several groups confirmed the 
DN effects using p53mutant/+ mice in various primary cell types, 
including thymocytes, splenocytes, and embryonic stem cells, 
by comparing it with the p53−/+ cohorts (15–18). Interestingly, 
while the DN effects were seen in some tissues, both on target 
gene activation and on cell survival, this was not the case in other 
cell types, as in primary fibroblasts in their growth, suggesting 
that the DN effect might be cell type, and possible stimulus 
dependent (18).
An interesting observation that emerges from all these stud-
ies with primary and transformed cells is that the DN effects on 
target gene activation and cell death are generally seen when 
cells are exposed to stress stimuli, including exposure to DNA-
damaging agents, when p53 is activated and stabilized (15, 16, 
18). By contrast, DN effect is not normally observed at baseline 
conditions, as there were no growth advantages to primary cells 
from p53mutant/+ mice, or with respect to spontaneous tumor 
development, both of which mirrors the p53−/+ cells and mice 
(18, 19). Furthermore, although the DN effect can lead to almost 
complete ablation of target gene activation when observed, all 
p53mutant/+ mice generated so far have not been able to rescue the 
embryonic lethality due to the absence of Mdm2 (15, 18). Thus, 
these data collectively surmise that the DN effect of mutant p53 
is exhibited when the levels of the mutant p53 is elevated in acute 
stress conditions, and thus, may have a significant consequence 
when patients are treated with chemotherapy and radiotherapy. 
However, a noteworthy point is that DN effects are not seen with 
respect to susceptibility to tumor formation, even in the case 
when p53mutant/+ mice have been irradiated, supporting the notion 
that DN effects observed upon acute activation of p53 that affects 
short-term apoptotic response do not have a contributory role to 
the long-term tumorigenic effects (18). Thus, acute p53 activation 
and DN effects of mutant p53 can be decoupled from the long-
term effects of p53 in regulating tumor susceptibility.
In this respect, early reports have suggested that at least three 
molecules of mutant p53 are required to impose a DN effect on 
one molecule of WT p53 (7, 20). Interestingly, although mutant 
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p53 protein has been shown to have a much longer-half life than 
WT p53, especially in tumor cell lines and in transfection stud-
ies, primary cells and tissues from p53mutant/+ mice do not exhibit 
elevated steady-state levels of the mutant p53 protein (18, 19). 
However, mutant p53 appears to be more abundant in tumor 
tissues from these mice, further alluding to the requirement of 
stress and/or oncogenic signals for mutant p53 stabilization (18, 
19). Given that stress signals are also able to further stabilize 
mutant p53, it is not unexpected that the ratio of mutant p53 to 
WT is significantly high, thereby leading to the observed DN 
effects. In supporting this theory, reduction of the endogenous 
mutant p53 levels – using an hypomorphic mutant p53 knock-in 
mouse model  –  was indeed shown to alleviate the DN effects, 
both on target gene activation and cell death upon irradiation 
(18). Similarly, reduction of the WT p53 levels in a p53mutant/+ 
mice strain also led to exhibition of the DN effect in tumors (21). 
Thus, these observations consolidate the case for the requirement 
of a significant increase in mutant p53 levels – as seen in tumor 
cells, or in primary cells upon exposure to stress stimuli – for the 
manifestation of the DN effects, which could be ameliorated by 
reducing the mutant protein levels. This implies that in a clinical 
setting, strategies that would reduce mutant p53 protein levels 
without an effect on WT p53 during therapy would lead to better 
efficacy of treatment and would be a future prospect that should 
be followed up.
Mechanistically, there are a few modes of operation of the 
DN effect. The mutant p53, which itself is unable to specifi-
cally bind to the p53-response elements, binds to the WT p53, 
thereby quenching it away from target gene promoters (6, 10). 
Alternatively, mutant p53 quenches away co-factors that are 
required for transactivation by the WT p53 bound to the pro-
moter, thereby reducing the potency of the WT protein (22). In 
addition, mutant p53 has been suggested to form aggregates, akin 
to those seen in protein misfolding diseases. Herein, it has been 
suggested that the WT p53 protein is engulfed into mutant p53 
fibrillar and granular aggregates, whereby the misfolded mutant 
protein sequesters the WT form, thus leading to inactivation of 
the WT function (23). Whatever the mechanism may be, the 
underlying concept is that the ability of mutant p53 to bind to 
wild-p53 when in excess is causal to the DN effect, which could 
thus offer an avenue for exploitation for therapeutic benefit. 
While there are currently no known ways of overcoming the DN 
effect, potential strategies that lead to the degradation of mutant 
p53 specifically without affecting the WT protein will be the way 
forward in ameliorating the DN effect.
AFTeR LOH – THe MUTANT p53-
ADDiCiTON PHeNOMeNON
While the phenomenon of addiction to oncogenes has been well 
established (24), mutated tumor suppressors have never been 
earlier reported to provide a survival advantage to tumor cells 
due to any novel acquired functions. However, two reports in the 
mid-2000s showed for the first time that silencing the expression 
of endogenous mutant p53 can lead to increased apoptosis (25), 
and reduced tumor growth in vivo (26), formally demonstrating 
the phenomenon of addiction of tumor cells to mutant p53’s 
presence. In addition, indirect evidence for the requirement for 
mutant p53 for survival of cells in a phospholipase D-dependent 
manner was also noted (27). This phenomenon is now well 
established in a large number of subsequent studies. However, the 
causal mechanisms are still relatively elusive. In earlier studies, a 
role for transactivation by mutant p53 of cell growth regulation 
genes was suggested, as the transactivation deficient DBD p53 
mutants were unable to provide a growth advantage (28). In the 
other studies, mutant p53-mediated suppression of canonical 
p53-target genes was suggested to be the mechanism, which was 
ameliorated upon the silencing of mutant p53 expression, leading 
to cell death. In this latter case, hypomethylation appeared to be 
involved, as trichostatin A – a HDAC inhibitor – was found to 
relief the mutant p53-dependent suppression (25). Other recent 
studies have confirmed this possibility, using other HDAC inhibi-
tors, such as SAHA (29) and sodium butyrate (30).
Recent in vivo work in mice has also confirmed that destabili-
zation of mutant p53 expression leads to apoptosis and reduction 
of tumor growth (31). In this case, mutant p53 was destabilized 
through the inhibition of the HSP90/HDAC6 chaperone machin-
ery that is often upregulated in cancers, collectively highlighting 
the mutant p53-addiction phenomenon, and that degradation of 
mutant p53 can indeed enhance tumor cell death and improve 
therapy. While addiction to mutant p53 appears to be critical for 
the survival of the cancer cell, the exact point at which they get 
addicted to mutant p53 is not understood. While the transformed 
cells could be expected to become addicted to the presence of 
mutant p53 at the point in time of loss of the remaining WT p53 
allele, it is likely that further events are required for this phe-
nomenon to occur. Moreover, whether addiction to mutant p53 
is a universal phenomenon in all cell types also requires further 
systematic analyses.
ROLe ReveRSAL FROM TUMOR 
SUPPReSSOR TO ONCOGeNe: GAiN OF 
NOveL FUNCTiONS
Similar to mutant p53 addiction, the direct advantages conferred 
by the presence of the mutant p53 protein have been understood 
primarily through cell culture studies where isogenic cell lines 
without p53 expression have been used to analyze the effects of 
the overexpressed mutant p53. These have resulted in the uncov-
ering of a plethora of gain-of-function (GOF) effects, almost all of 
which provide survival/growth advantage to the cell. First direct 
evidence came from the overexpression of several human (e.g., 
R175H, R248W, R273H, and R281G) and mouse mutants in p53 
null cell lines that lead to increased cellular growth in soft agar 
and increased tumorigenicity in immunocompromised mice 
(32). While this was the first case of evaluating the effects of the 
mutant version of the natural tumor suppressor, earlier studies 
using a mutant p53  –  at that time thought to be the natural 
existing form prior to the knowledge that p53 is actually a tumor 
suppressor  –  also showed growth advantage due to its overex-
pression (33). In addition, there are multiple other parameters 
associated with genomic instability that were noted due to the 
December 2015 | Volume 5 | Article 2765
Sabapathy Functional Consequences of Mutant p53
Frontiers in Oncology | www.frontiersin.org
overexpression of mutant p53, including gene and centrosome 
amplification and disruption of spindle checkpoint (34–37). 
Consistently, overexpression of mutant p53 also led to resistance 
to death induced by a variety of chemotherapeutic drugs and 
DNA-damaging agents (38–41), as well as by anoikis (42). More 
recently, expression of mutant p53 was also shown to enhance the 
Warburg effect on cancer cells, promoting GLUT1 translocation 
to the plasma membrane, and thus enhancing glucose uptake 
(43).
Not unexpectedly, many studies have also evaluated if the 
expression of mutant p53 would enhance cellular invasion and 
migration and found that to be the case in a variety of 2D and 3D 
cellular systems (18, 44–46). Furthermore, a role for mutant p53 
in promoting cellular reprograming was also demonstrated (47), 
suggesting that mutant p53’s presence would lead to the survival 
and replenishment of the potential cancer stem cells, leading to 
their ability to colonize the adjacent territory.
At the organismal level where mutant p53 is expressed from 
its own locus  –  reflecting the status in human cancer condi-
tions – GOF properties were also noted with the generation of 
the p53 mutant knock-in mice. The initial data demonstrated that 
the p53R172H mice (equivalent to human R175H) were more tumor 
prone with more carcinomas  –  reflecting a change in tumor 
spectrum. They also had increased metastasis compared to the 
p53 null mice, in the absence of Mdm2, which leads to increased 
mutant p53 levels (15, 16). Further studies have cemented these 
findings, where the presence of the R172H mutant p53 protein 
conferred significant growth and metastatic propensity to tumors 
compared to the loss of p53, in several oncogene-induced models, 
including Ras and APC, in a variety of tumor types such as lung 
and pancreatic ductal adenocarcinomas (46, 48, 49). Similar 
observations were also noted with other mutations, such as the 
R270H and R273H in breast and lung cancer models (50, 51). 
These data mooted the idea that all mutant p53 would have GOF 
properties, and that this may depend on the stabilization of the 
mutant p53 in the cancer cell context, as normal untransformed 
tissues from the mutant p53 bearing mice did not have significant 
growth advantage and did not display increased steady-state lev-
els of the mutant protein (19). However, this theory came under 
challenge through the analyses of another hot-spot p53 mutant 
knock-in mouse strain (the R246S, equivalent to human R249S). 
In this case, the R246S mutant mice did not display any tumor 
latency difference or metastatic advantage even in the absence 
of Mdm2 (18). Similar results were also seen with other hot-spot 
mutant knock-in mice strains, in which the R248Q had a strong 
GOF phenotype in contrast to the G245S mutant (52), collectively 
alluding the fact that GOF may not be a universal phenomenon, 
and that elevation of mutant p53 levels may not be sufficient for 
their exhibition.
Nonetheless, as observed in the cell culture-based studies, there 
was a propensity to have more hematopoitic or mesenchymal stem 
cells in the R248Q mutant p53 knock-in mice, indicative of an 
effect of mutant p53 on the plasticity of the stem cell population 
(52). Besides the effects on tumor metastasis and aggressiveness, 
the effects of mutant p53 on several other aspects of physiology 
have been noted using the knock-in mice strains. For instance, 
there was increased inflammation and tissue damage, primarily 
due to upregulation of inflammatory cytokines that were induced 
by mutant p53-mediated prolonged activation of NFKB signal-
ing (53). Angiogenesis was also shown to be enhanced due to 
mutant p53 expression, through the activation of ID4 expression 
in cell culture studies (54). These studies collectively indicate that 
expression of mutant p53 in tumor cells, as seen in the case with 
human cancers, as well as in normal tissues as analyzed from 
animal studies, has far-reaching consequences on organimsal 
physiology.
While enormous amounts of data from cellular systems 
and animal models highlight the existence of GOFs of mutant 
p53, albeit to varying degrees perhaps depending on several 
contextual factors, the main question is the relevance of this 
phenomenon in humans. A noteworthy point is that humans 
generally do not carry a mutant p53 allele in non-transformed 
tissues, except in the case of the Li–Fraumeni patients. Thus, the 
GOF properties would be of relevance in the large majority of 
tumors that eventually retain only the mutant allele. On the other 
hand, the Li–Fraumeni patients would be expected to have one 
allele that is WT in all untransformed tissues, except in cases 
where LOH would result in or occur with other transforming 
events that lead to tumorigenesis. In this context, transcriptomic 
analyses of p53−/− vs. p53mutant/mutant primary tissues (e.g., thymus) 
from the knock-in mice remarkably did not reveal any significant 
changes (18), highlighting that GOF is generally not observed in 
untransformed cellular contexts. Thus, even in the Li–Fraumeni 
group, the GOFs and addiction to mutant p53 would be a 
phenomenon that would be of relevance primarily in the cancer 
cell context. This has been exemplified in a large number of 
studies that have evaluated the role of mutant p53 in response 
to chemotherapy, which have generally shown poor prognosis 
associated with the presence of mutant p53 (55). This, however, 
could either be due to the DN effect or the GOF functions, as 
many of these reports have not teased out the status of the other 
allele in the patient samples. Thus, the presence of mutant p53 in 
human tumors does indeed exert a negative effect in response to 
therapy, warranting in-depth investigations into the mechanisms 
of actions of mutant p53.
MeCHANiSMS AND MeDiATORS OF 
MUTANT p53 GAiN-OF-FUNCTiONS
Since the demonstration of GOF of mutant p53, extensive efforts 
have gone on to examine the mechanistic basis of this phenom-
enon [reviewed in Ref. (56)]. At least four inter-related categories 
of actions have emerged: novel target gene activation through 
direct DNA binding; enhancement of target gene activation due 
to co-factor binding to mutant p53; co-operation with other tran-
scription factors to activate other transcriptomes; and binding to 
factors that indirectly result in activation of other pathways.
In the first instance, while DBD-mutant p53 has lost its abili-
ties to bind to canonical p53-responsive elements on target gene 
promoters, several studies have alluded to the ability of mutant 
p53 to bind to novel target gene promoters to activate them. It has 
been proposed that mutant p53 interacts with matrix-attachment 
regions (MARs), thereby recognizing structures rather than 
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sequences (57). This results in the activation or repression of 
mutant p53-target genes, the list of which has been steadily 
growing. In brief, the targets can be categorized into either genes 
that are upregulated or down-regulated by the presence of mutant 
p53, including both coding and non-coding genes involved in 
promoting proliferation, inhibiting cell death, promoting migra-
tion, and inflammation. In the former category exists a large array 
of genes, including growth factors/receptors, such as bFgF, Egfr, 
Igf1, Igf1r, IL6, and TNFα; cell death/survival genes, such as bcl-xl, 
procaspase 3; oncogenes and transcription factors, such as c-fos; 
c-Myc, Egr1, Nfkb, Ras, and Egr1; metastasis regulators, such as 
twist-1; microRNAs, such as mir 155 and mir128-2; and many 
others [reviewed in Ref. (2)]. The second category of suppressed 
genes includes Fas, Mst-1/msp, mir130b, mir27a, mir 223, and 
also a large array of the canonical p53-target genes that appear to 
be suppressed by the presence of mutant p53 (25).
Next, regulation of target genes by mutant p53 can be facilitated 
by co-operative binding and post-translational modifications of 
the mutant p53 protein. For instance, mutant p53’s activity has 
been shown to be enhanced by binding with PML and Pin1 (58, 
59). In addition, mutant p53 has also been shown to co-operate 
with other transcription factors, such as NF-Y, VDR, Sp1, and 
SREBP, to enhance the activation of their target genes (60–63). 
Conversely, mutant p53 has also been shown to bind to p63 and 
p73 to inhibit the activation of the latter groups’ targets (64). 
Finally, an indirect role for mutant p53 in activation of various 
pathways has emerged. For example, mutant p53 has been shown 
to bind to p63, thereby negating the latter’s inhibitory effects on 
the α5β1/RCP complex, which leads to enhanced cellular motility 
(46). Similarly, mutant p53 has been shown to bind to proteins in 
the DNA-repair pathway, such as MRE11, thereby affecting their 
functions, which leads to increased genomic instability (65).
The diversity in mechanisms and mediators of mutant p53’s 
GOF function allude to the fact that these may be dependent and 
vary according to the cell type, the mutation type or the stimuli. 
Furthermore, GOFs would also likely be temporally dictated dur-
ing the evolution of the transformed cell. Hence, efforts aimed 
at targeting mutant p53 would have to take into account these 
factors that have to be elucidated and characterized.
FUTURe OF MUTANT p53
One can envisage that all the years of work on mutant p53 and 
its functions will now put the research community in good 
stead in trying to target its functions for clinical benefit, and 
the current status of these efforts is reviewed in the adjoin-
ing chapters. Nonetheless, important considerations have yet 
to be worked out. These include several questions, such as 
how can the DN effect be mitigated when treating patients 
whose tumors retain the WT allele; what is the effect of the 
DN phenomenon in the daily lives of LF patients, especially 
when they are exposed to a variety of signals that may have 
an acute effect on p53 activation; precisely when and where 
is GOF manifested and addiction to mutant p53 occur; and 
what is the trigger point for GOF of mutant p53. Thus, while 
general targeting strategies are being worked out, more work 
is required to realize the dream of targeting all types of 
mutant p53 that are different, and thus, likely require specific 
molecules/dugs to counter them.
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